Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. - Wikidata - awgldk - TriplyDB

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

http://www.wikidata.org/entity/Q39506626

about

Adoptive T-Cell Immunotherapy Adoptive cell therapy for sarcoma Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies T-cell receptor gene therapy--ready to go viral?Reversal of tumor immune inhibition using a chimeric cytokine receptor.Engineered T cells for cancer treatment Interleukin-7 and Immunosenescence.IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Immunotherapy of human cancers using gene modified T lymphocytes.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Genetic modification of T cells Adoptive T cell therapy of cancer.Engineered T cells for pancreatic cancer treatment Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Treatment of lymphoma with adoptively transferred T cells.Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.Genetic redirection of T cells for cancer therapy.Designing T cells for cancer immunotherapy Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Progress and prospects: graft-versus-host disease.Cellular immunotherapy for high-grade glioma.Ex vivo gene transfer for improved adoptive immunotherapy of cancer.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.Genetic engineering of T cells for the immunotherapy of haematological malignancies.Challenges in T cell receptor gene therapy.CD28z CARs and armored CARs A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Current Studies of Immunotherapy on Glioblastoma Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Immunotherapy against cancer-related viruses.

P2860

Q26782845-CCBCD0E5-A81B-4AA9-AF8D-AC5C04453DF1 Q27009541-F4FD5A4C-7323-47CE-9A8E-33F68DDA4F4F Q27027243-7A0AC3E4-0B70-408A-9660-972FED5AC244 Q28081611-21ABBA25-24A7-4824-B941-9A144892F732 Q30580134-C7FA28E5-E567-4B31-8F38-435D9744C962 Q33578792-40335B09-379A-4B4F-8C4E-AD69AD808047 Q33582101-35A775A5-591A-4153-A627-39ACF8BA5586 Q33839836-DA062318-12CF-43CC-935F-5DDDA11B99B9 Q34044757-6C622B48-0D49-4829-B6C1-33E404F6095D Q34122292-6D57B52F-564A-4160-A445-FC00ED673BC4 Q34188383-DAF400DB-2C7A-4014-BC4B-E93DAEBC949F Q34205181-64DA0434-8FF6-44A9-A710-7346FDD6A7F9 Q34644876-2C6F4806-FB1B-4C7E-978F-8FF8ED4C9455 Q34977470-E0F8A24B-1631-496C-AAAC-8CBB4A4E82A8 Q35244233-18DD1A17-C124-49E9-9CC5-9DA3CA941679 Q35623465-B958E49E-5AC9-4C3A-B6AA-6FBDFC3A7805 Q36014997-E71807BB-DDCD-4737-A62D-3C589779C67F Q36366557-D53AE1E9-18A9-461E-81BD-1406EFE5517C Q36470354-98CB0A5F-D472-4B28-9657-377A91851D46 Q36616920-E348B9C5-5D38-4280-8B12-D92EBB0CC4DB Q37058110-6428AD09-B1A3-41E9-A01E-B4973DBD4B1B Q37419728-7A7A1AD9-C6E9-4FAF-B74A-218656E79807 Q37450543-407D8245-FE6E-4290-800C-FCBDA589B25E Q37469199-D191E14F-9ED9-44BB-B2F4-1FABE536AC0B Q37585288-2000D16C-F125-47CC-97D6-A405FE08E0CB Q37653325-9F95BF2E-AF09-493A-B278-8683AA3DF8FF Q37697337-2499452C-0DA4-4099-83E8-21F0306789DF Q37737817-8A262466-EF3C-4A69-A414-2459215E4AC2 Q37751873-80F622AE-2434-448C-B82B-6F42CD5F47C3 Q37761297-233EEEE4-AAF7-47A4-A4C7-BA3E610CB9BC Q37851972-EA61417A-162A-4E1B-9806-67B204D38519 Q37854259-003EEAC7-DEA3-4973-9370-A3C4CC1F073E Q37861192-7E37EF91-9C19-4225-8C29-9C8D0AB35660 Q37965815-8C597B5A-CCFF-43C3-80AB-804946BF6191 Q38011650-D3BBB66F-BD3A-4565-B89B-76481A99D058 Q38199347-3821A361-023B-4100-9B22-3F360AADD1C7 Q38227889-AB0156F7-E1C4-4B9A-9A41-32FC6F513372 Q38262914-A40007C3-9E31-4830-ADA2-BF3354C64999 Q38719148-2C93FA93-3E61-4EFC-94CC-C55779971508 Q38778924-B496495E-EEB3-4001-A4DD-1E713950B468

P2860

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

http://www.wikidata.org/entity/Q39506626

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@en

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@nl

type

label

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@en

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@nl

prefLabel

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@en

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@nl

P1433

Q39506626-D317F3FB-6405-40CA-945F-1778EF333A7E

P1476

Q39506626-2B6DDA51-1429-44B5-BCFD-8490445C0B0D

P2093

Q39506626-01FB21C8-E39A-4481-A54A-4BF6FF74279E

Q39506626-0F313527-A6DD-48E8-B0F4-006EE9BFE0F7

Q39506626-168D1A73-FBB0-4C3A-ABEC-B4804024DD88

Q39506626-242EC43D-A0A6-4938-92C4-B25857373E82

Q39506626-4019367B-2974-41F5-8C86-A26046807D37

Q39506626-50133EA3-D4F2-4ED2-B8F1-1664BA3905E5

Q39506626-663B7F04-7207-439B-B6FD-129973E8B5EB

Q39506626-A263BA11-6727-40BA-874C-830E1AC30F4C

Q39506626-BD5E166D-98FF-43BD-8A48-C8956809CBEE

Q39506626-D9C80C21-DFBB-4211-A48B-C0A088F04993

P2860

Q39506626-054BE3F5-D537-4084-8208-7DB98F7D2A41

Q39506626-0C0355FD-F6DF-4F0E-B327-531075902067

Q39506626-0C4FBB28-6E15-4E43-8E65-297F8FEDE890

Q39506626-1034D2CE-559A-4DDC-B30C-650C5FD3F0B1

Q39506626-1420856C-10DE-42D6-AEEE-DEAAF875188A

Q39506626-18AA1C9F-2668-49C3-9FE7-560F9A568770

Q39506626-191E0E87-D59F-44EE-883D-1120202DF9A3

Q39506626-1D432995-236A-44C2-9DDC-04090F07C2D8

Q39506626-2334779C-0F0B-49D6-A79B-0367D80A50D4

Q39506626-27EEDF0C-022F-4366-89C8-2E13BD574FB8

P304

Q39506626-F36EF364-DC28-4967-B905-CD7E68ED0D53

P31

Q39506626-E1560F8B-098B-4248-9102-DDB1BA5C03A3

P356

Q39506626-392E021B-023D-4E50-B884-582E27B942D2

P433

Q39506626-23525724-55BB-428A-A19B-BA3094B4C14F

P478

Q39506626-D3D2B6A0-4E73-4578-B3EA-9B26020CD224

P577

Q39506626-A994E469-A0FA-4CBC-9108-F5DDA5EE5DD4

P5875

Q39506626-04A0F932-ED6D-4EF6-BCFC-0A7757CFEC94

P698

Q39506626-8DC63803-0022-4631-B95B-EDD9B76CD27B

P921

Q39506626-DD100333-EF5C-424C-9E33-F0910DE39F79

P932

Q39506626-9C2B003A-2EBD-4106-89DC-B47D177291F1

P356

P1433

Molecular Therapy

P1476

Genetic manipulation of tumor- ...... estore responsiveness to IL-7.

@en

P2093

Aaron E Foster

http://www.w3.org/2001/XMLSchema#string

Ann M Leen

http://www.w3.org/2001/XMLSchema#string

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Concetta Quintarelli

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Greta M P Giordano Attianese

http://www.w3.org/2001/XMLSchema#string

Hao Liu

http://www.w3.org/2001/XMLSchema#string

Helen E Heslop

http://www.w3.org/2001/XMLSchema#string

Juan F Vera

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.

P304

880-888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.34

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24175209

http://www.w3.org/2001/XMLSchema#string

P698

19259067

http://www.w3.org/2001/XMLSchema#string

P921

P932

2835146

http://www.w3.org/2001/XMLSchema#string